INTRODUCTION
According to an estimate, the world population of the elderly is increasing and by the year 2050, adults older than 65 years will comprise 1/5th of the global population. In India, 3.8% of the population are older than 65 years. 1 Globalization and Westernization has changed the worldly outlook of people and aging is now having more implications to the individual and society as this process has now taken a new socioeconomic dimension. 2 Accordingly, Geriatrics is emerging as a major medical specialty worldwide. Conventional system of medicine has nothing much to offer in the core areas of geriatric care except the medical management of the diseases of old age. On the contrary, Ayurveda considers geriatric care as one among the eight branches of Astanga-ayurveda. 3 Aging is a process of gradual physical, psychological, and social change in multidimensional aspects. The main issue in geriatric care is not merely the concern about the physiological phenomenon which is inevitable; rather, it is more about the medical health problems and diseases specifically afflicting an individual in old age warranting medical management in order to sustain a comfortable and healthy life. Aim of Rasayana Chikitsa is to address two-fold problems; retard the rate of physiological aging; and manage any diseases that arise due to aging. 4, 5 Ayurveda, being fundamentally the science of life and longevity, seems to have addressed these issues in a unique holistic manner involving not merely the biological care but also encompassing the psychosocial and spiritual dimensions. There are strong possibilities to develop a safe and cost-effective package for geriatric care through incorporation of Ayurvedic lifestyle management, Rasayana therapy and practice of Yoga.
According to Charaka Samhita, use of Rasayana helps in attaining longevity, memory, intelligence, health, youthfulness, excellent complexion, luster, voice quality, strength of body and sense organs, and produce excellence of Rasadi Dhatus. 6, 7 Rasayana can bring about harmony of deranged dosha in the body and prevent augmented rate of natural degeneration in the body. Rasayana provides drug base therapy and remedial measure in the form of pathya, prasamana, and prakrtisthapaka. 8 The study was undertaken to evaluate the Rasayana effect and clinical safety of Chyavanaprasha in apparently healthy elderly individuals.
AIMS AND OBjECTIvES
To evaluate the efficacy and safety of Chyavanaprasha in improving general body health and QOL in apparently healthy elderly subjects.
MATERIALS AND METHODS

Study Design
An open-labeled prospective multicenter clinical trial was conducted at three peripheral centers of Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of AYUSH. The study protocol and related documents were reviewed and approved by the Institutional Ethics Committee of each participating center and the study was done in accordance with WHO-Good Clinical Practice Guidelines. The trial has been registered in the Clinical Trial Registry of India (CTRI/2016/03/006701).
Study Participants
A total of 214 subjects were enrolled in the trial from three peripheral institutes of CCRAS, viz., Dr. Achanta Lakshmipathi Research Centre for Ayurveda (ALRCA), Chennai; Central Ayurveda Research Institute for Cancer (RRAPCARIC), Mumbai; Regional Ayurveda Research Institute for Metabolic Disorders (RARIMD), Bengaluru, India. Patients were screened in accordance with the inclusion and exclusion criteria mentioned in the protocol and were recruited in the study after obtaining their written informed consent.
Inclusion Criteria
Apparently healthy males/female volunteers of age between 60 and 75 years and those who were willing to participate for 12 weeks were included.
Exclusion Criteria
Patients with evidence of malignancy; those who had participated in similar study previously or participating in any ongoing study; patients suffering from systemic illness necessitating long-term drug treatment (rheumatoid arthritis, psychoneuroendocrinal disorders, etc.); patients suffering from cardio vascular diseases, diabetes mellitus with >6% glycated hemoglobin (HbA1c); patients with concurrent hepatic disorder (defined as aspartate aminotransferase and/or alanine aminotransferase >2 times upper normal limit) or renal disorders (defined as serum creatinine > 1.2 mg/dL); patients with pulmonary dysfunction (bronchial asthma and/or chronic obstructive pulmonary disease ; inflammatory bowel disease, severe dementia, severe infection(s), nonambulatory patients or any other condition that may jeopardize the study; alcoholics or drug abusers and other psychiatric diseases; patients whose participation in any other clinical trial during the past 6 months or any other condition which the investigator thinks may jeopardize the study in any way were excluded from the trial.
Study Interventions
Chyavanaprasha [Ayurvedic Pharmacopoeia of India (API), Part-II, in the form of lehya was administered in a dose of 12 gm twice daily on empty stomach along with milk in the morning and evening for a period of 12 weeks (i.e., 84 days). The formulation was procured from good manufacturing practice-certified Ayurvedic Pharmaceutical Company and standardized following the standards laid in API.
Chyavanaprasha Ingredients
Chyavanaprasha
10 is a time-tested Rasayana that has been mentioned in classics, having more than 40 ingredients. The chief ingredient of Chyavanaprasha is Amalaki, which is a known antioxidant and rich source of vitamin C (Table 1) .
JRAS
Study Procedure
On screening visit, subject's voluntary written informed consent was taken. On the enrolment day at baseline (Visit 1), patient's demographic profile, medical history, family history, sharirik prakriti vital parameters, assessment of QOL using WHO QOL BREF scale and assessment of 6 MWT were recorded. Subsequent visits were planned at an interval of 14 days [14th day (Visit 2), 28th day (Visit 3), 42th day (Visit 4), 56th day (Visit 5), 70th day (Visit 6), and 84th day (Visit 7)]. Patients were assessed and given study medications at each subsequent visit till 84th day. There was also without medication followup after every 14 days after the 84th day visit. Details of clinical assessment and study schedule are given in Flow Chart 1.
At the study site, data of all the subjects were recorded in predesigned Case Report Forms (CRFs) and was also entered in electronic formats (e-formats) designed in MSExcel with many data validation checks to ensure correct data entry. The e-format and Xerox of the CRFs along with laboratory investigations reports of the subjects were sent by the participating centers to the Council's (CCRAS) headquarters on weekly basis for the purpose of clinical trial monitoring.
Out of the total 214 subjects enrolled in the study, 11 dropped out during the course of the study. Intentionto-treat analysis was done and the data of all those participants who have completed at least 14th day visit were imputed by last observation carried forward (LOCF) 
Jeevaka (Microstylis muscifera)
Rushabhaka (Malaxis muscifera)
Shati (Hedychium spicatum )
Prakshepaka dravyas (twak, ela, patra) Flow Chart 1: Study schedule method. Hence, data of total 214 subjects/participants were used for statistical analysis (Flow Chart 2).
RESULTS
Outcomes
Primary outcome measures were changes/any improvement in metabolic profile or changes in the laboratory parameters. The secondary outcome measures were any change (improvement) in functional exercise capacity by 6 MWT (6-MWT measures the distance an individual is able to walk over a total of 6 minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in 6 minutes. The individual is allowed to selfpace and rest as needed as they traverse back and forth along a marked walkway. The 6-MWT was developed by Balke 11 to evaluate functional capacity) and changes in QOL using WHO QOL BREF scale 12 (from baseline to the end of 12th week); The four domain scores denote an individual's perception of QOL in each particular domain. Domain scores are scaled in a positive direction, i.e., higher scores denote higher QOL. The mean score of items within each domain is used to calculate the domain score. Mean scores are then multiplied by 4 in order to make domain scores comparable with the scores used in the WHO QOL-100).
Statistical Analysis
Primary outcome and secondary outcome measures, i.e., metabolic profile, laboratory parameters, changes in QOL using WHO QOL and functional exercise capacity by 6 MWT were analyzed as mean change in the response from baseline to 84th day by using paired t-test. A p-value of <0.05 was considered significant. Analysis was carried out using Statistical Package for the Social Sciences version 15.0. Data of a total 214 subjects (122 males and 92 females) were used for statistical analysis. Out of which, maximum subjects, 113 (52.8%) were in the age group of 61 to 65 years. Table 2 shows the demographic profile of the subjects. Seventy-seven (27.3%) subjects were of Pittakaphaja sharirik prakriti, followed by vata-pittaja 56 (19.9%).
It was also observed from the data that 171 (79.9%) of the subjects were married; 193 (90.2%) were literate enough to read and write. Maximum number of subjects, 112 (52.3%) were housewives and were indulged in domestic work, which included physical labor also. Maximum numbers of subjects, 205 (95.8%) were residing in urban area. It was also noticed that 79 (36.9%) subjects were vegetarians, while 135 (63.1%) subjects were nonvegetarians, addiction of any kind was not found in 171 (79.9%) subjects, while smoking and chewing tobacco were observed in 10 (4.7%) and 11(5.1%) respectively; 187 (87.4%) subjects were nonalcoholic and 27 (12.6%) had the habit of taking alcohol occasionally.
Vital parameters of the subjects recorded at baseline are shown in Table 3 . Mean systolic blood pressure was 123.06 and mean diastolic blood pressure was 79.30. Mean pulse rate and respiratory rate was 74.10 and 16.41 respectively at baseline.
Effect of the study medications was also assessed by paired t-test on hematological parameters and metabolic Flow Chart 2: Details of the study profile compared between baseline and 84th day. No statistically significant changes were observed in these parameters. Table 4 and Graph 1 shows the results of the analysis on hematological parameters and metabolic profile like high-sensitivity C-reactive protein (hs-CRP), sugar levels, HbA1c, and lipid profile. There was no significant change in serum cholesterol, serum triglycerides, random blood sugar, postprandial blood sugar, total leukocyte count (TLC), or erythrocyte sedimentation rate (ESR) at the end of the trial period, which implies that it is safe to be used in elderly patients, without the risk of getting afflicted with such diseases.
Safety Profile
The effect of this treatment on various safety parameters, such as LFT and renal function test (KFT) were assessed on baseline and on 84th day visit. The values are within the normal limits before and after the trial. Table 5 and Graph 2 show the effect of Chyavanaprasha on the safety parameters.
Assessment Parameters
Effect of study medication was assessed by paired t-test on changes (improvement) in functional exercise capacity by 6 MWT and changes in QOL using WHO QOL BREF compared between baseline and on 84th day. Table 6 , Graphs 3 and 4 show the effect of the drugs on the assessment parameters. In all the domains of WHO QOL BREF score, physical health, psychological health, social relationships, and environmental aspects, statistically significant change (p < 0.001) was observed at the end of the trial period. This signifies the role of Rasayana in providing nourishment to rasadi dhatu. All round betterment is produced by Rasayana in physical, mental, and social health of apparently healthy elderly persons. $ Compared using paired t-test at baseline and 84th day, *p-value of <0.05 has been considered as significant; SGPT: Siamane glutamate pyruvate transaminase; SGOT: Serum glutamic oxaloacetic transaminase A significant increase (p < 0.001) in 6 MWT and QOL was seen from baseline value and at the end of the treatment period, which implies that Rasayana is effective in enhancing the level of physical activity, which is an indicator of improved status of body tissues, specifically blood, muscle, and bone.
Effect of the study medications was assessed in improving the subjects functional capacity in terms of Ahara Shakti (Appetite) and Vyayama Shakti (Exercise) when compared with baseline to 84th day and the data is given in Table 7 . There was significant improvement in Aharashakti of the individuals at the end of the trial period. The number of individuals with Pravara Agni increased from 16 (7.5%) to 117 (54.7%). Vyayama Shakti improved to Pravara in 145 (67.8%) when compared with 94 (43.9%) at baseline.
DISCUSSION
Aging is defined as a progressive breakdown of homoeostatic adaptive responses of the body. The consequences The primary action of Chyavanaprasha is to strengthen the immune system and to support the body's natural ability to produce hemoglobin and white blood cells. 16 It is effective in bala, vridha, and kshata ksheena for dhatu pushti and is effective in cardiovascular diseases, cough, dyspnea, rheumatic diseases, and diseases of urogenital tract. 17 It can compensate the action of prakupita vata, augment agni, promote intellect, and provide clarity for mental attributes and virility. 18 As a result, it is a highly admired Rasayana, offering deep nourishment to the tissues, preserving youth, and promoting systemic health and wellbeing. 19 The statistical analysis of the results of the effect of drug on outcome parameters shows that it has produced highly significant change in functional exercise capacity by 6 MWT by 84th day, compared with baseline with p < 0.001. The increase in the distance walked indicates improvement in basic mobility, which might be due to increased efficiency of musculoskeletal system. Statistically significant change was observed in four parameters of WHO QOL BREF scores: Domain 1 (physical health) (p < 0.001), Domain 2 (psychological) (p < 0.001), Domain 3 (social relationship) (p < 0.001), and Domain 4 (Environment) (p < 0.001) at 84th day compared with baseline. This proves that Chyavanaprasha has produced multilevel improvement in QOL of individual. It was also observed that Aharashakti (Appetite) and Vyayama Shakti (Exercise) of the participants improved when compared before and after the trial. No significant change was observed in metabolic or hematological parameters during the entire trial period, which proves that this can be used as a general nourishing lehya.
Safety parameters like LFT and KFT were assessed on baseline and on 84th day visit. These values were observed to be within the normal limits during and after the study, and hence this formulation can be considered safe for use, even in elderly people.
Chyavanaprasha can be considered as a drug with excellent action in the human body in molecular and tissue level as it acts by reducing the rate of natural cell senescence in the body, improves body performance, brings clarity to mind, and rejuvenates the body as a whole.
CONCLUSION
The properties or beneficial effects of Rasayana mentioned in the classics can be correlated with Adaptogenic property. 20 These Adaptogens normalize body functions, strengthen systems, promote homeostasis, and have a protective effect against a wide variety of cellular stress.
As described by enlightened sages in classical Ayurveda, the functional exercise capacity, physical, psychological, social, and environmental aspects as mentioned in the WHO QOL has been improved with Chyavanaprasha. It can be concluded that "Chyavanaprasha" is very much effective in improving the QOL, functional exercise capacity, and other physiologic activities in terms of Ahara Shakti (Appetite) and Vyayama Shakti (Exercise) of the apparently healthy elderly participants due to Vayashtapana (age-stabilizing) property of Chyavanaprasha.
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